Abiopharma

🔍 Gerry Christopher (Executive)

Company: Sensei Biotherapeutics, Inc. (SNSE)

Report Date: 2026-06-10

Detailed Transactions and Holdings:

• Acquired 220,000 shares of Stock Option (right to buy) at $29.89 per share (Derivative)
  Date: 2026-06-10 | Code: A | Expires: 2036-06-09 | equity_swap_involved: 0 | shares_owned_after: 220,000.00 | transaction_form_type: 4 | Footnotes: F1, F2

Footnotes:

• F1: The stock option grant was approved by the Issuer's Board of Directors on April 10, 2026, subject to stockholder approval of the 2026 Equity Incentive Plan, which approval was obtained on June 10, 2026. The exercise price reflects the closing price of the Issuer's common stock on April 10, 2026.
• F2: 25% of the shares subject to the option vest and become exercisable on April 10, 2027, and the remaining shares vest and become exercisable in 36 equal monthly installments thereafter, such that the option is fully vested on the fourth anniversary of the vesting commencement date, or April 10, 2030, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.